Division of Cardinal Health Inc.
Latest From Cordis Corp.
Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, but BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings.
The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.
It was a busy summer for Chinese pharmaceutical companies and investors who went global shopping, eying mega acquisition deals since China announced plans to accept overseas clinical trial data and global multicenter studies as part of its policies.
April was a return to a more typical volume of medical device approvals outside the US after a particularly busy March. And the big names in medtech were mostly quiet in April's OUS approvals, according to Medtech Insight's Approval Tracker.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Cardinal Health Inc.
- Senior Management
- Rick Anderson, Chmn.
- Contact Info
Phone: (800) 447-7585
6500 Paseo Padre Pkwy.
Fremont, CA 94555
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.